Comprehensive procedure for injecting Evusheld® for hematological diseases in a single institute
Abstract
Tixagevimab
and
cilgavimab
(EVA,
Evusheld®),
monoclonal
antibody
combination
treatments,
consisted
of
two
neutralizing
antibodies
against
severe
acute
respiratory
syndrome
coronavirus
2
(SARS-CoV-2).
EVA
showed
prophylactic
therapeutic
effects
disease
2019.
The
Japanese
Society
Hematology
recommended
for
such
patients
with
active
treatment,
but
each
institution
decided
on
comprehensive
administration.
We
develop
a
systematic
procedure
injection
in
hematological
malignancies
without
any
over/under-indication.
listed
all
the
required
indications
from
November
2022
to
March
2023.
included
178
cases,
84
females
94
males,
median
age
70
(range:
19–90)
years.
Underlying
diseases
are
myeloid
neoplasms
36
(20%),
lymphoid
75
(73%),
others.
Indications
were
intensively
malignancy
rituximab
treatment
within
12
months,
burton
kinase
inhibitor
after
chimeric
antigen
receptor
T
cell
immunotherapy,
stem
transplantation
74
(41%),
73
3
(2%),
5
(3%),
23
(13%)
respectively.
Of
22
(12.4%)
refused
injection.
Further,
42
136
cases
administered
outpatient
inpatient,
Over
95%
received
months.
No
toxicities
observed
among
them
(N
=
156),
8
(5.2%)
had
breakthrough
SARS-CoV-2
infection,
which
was
significantly
lower
(P
0.02)
than
those
(4
[18.2%]
cases).
Both
groups
no
moderate
or
infection
cases.
This
single-center
experience
that
management
effectively
generated
safer
completion
preferable
clinical
impact.
Research Square (Research Square), Journal Year: 2024, Volume and Issue: unknown
Published: Jan. 29, 2024
Language: Английский